Alexandre Nguimfack, Eudoxia Filipe, Dercio Filimao, José Mizela, Erica Bila, Mercia Matsinhe, Maria Inês Tomo de Deus, Irenio Gaspar, Maria Ruano, Luis Armando, Orrin Tiberi
Introduction: Advanced HIV Disease (AHD) is a remaining hurdle in the care and treatment cascade in Mozambique and has the potential to delay Mozambique's progress towards the UNAIDS 95-95-95 goals for 2025. An improved understanding of the prevalence and demographics of people with AHD is critical to address this important condition.
Methods: Data were reviewed from October to December 2023 from the 79 health facilities at a national level implementing the AHD diagnosis and treatment package at the national level.
Results: Overall, 36% (7.811/21.452) of people living with HIV new initiated or reinitiated on antiviral treatment had a CD4 test, of which 1.986 were diagnosed with AHD (25%). Most of the diagnosed cases were in people living with HIV that were newly initiated (1.814) versus those being reinitiated (179).
Conclusion: The low coverage of CD4 testing in eligible patients is an obstacle to the early identification of AHD patients and the reduction of mortality, and consequently a barrier to HIV elimination in Mozambique.
{"title":"Doença Avançada por HIV em Unidades Sanitárias Seleccionadas em Moçambique, Outubro-Dezembro de 2023.","authors":"Alexandre Nguimfack, Eudoxia Filipe, Dercio Filimao, José Mizela, Erica Bila, Mercia Matsinhe, Maria Inês Tomo de Deus, Irenio Gaspar, Maria Ruano, Luis Armando, Orrin Tiberi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Advanced HIV Disease (AHD) is a remaining hurdle in the care and treatment cascade in Mozambique and has the potential to delay Mozambique's progress towards the UNAIDS 95-95-95 goals for 2025. An improved understanding of the prevalence and demographics of people with AHD is critical to address this important condition.</p><p><strong>Methods: </strong>Data were reviewed from October to December 2023 from the 79 health facilities at a national level implementing the AHD diagnosis and treatment package at the national level.</p><p><strong>Results: </strong>Overall, 36% (7.811/21.452) of people living with HIV new initiated or reinitiated on antiviral treatment had a CD4 test, of which 1.986 were diagnosed with AHD (25%). Most of the diagnosed cases were in people living with HIV that were newly initiated (1.814) versus those being reinitiated (179).</p><p><strong>Conclusion: </strong>The low coverage of CD4 testing in eligible patients is an obstacle to the early identification of AHD patients and the reduction of mortality, and consequently a barrier to HIV elimination in Mozambique.</p>","PeriodicalId":520426,"journal":{"name":"Revista mocambicana de ciencias de saude","volume":"10 2","pages":"18-22"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号